Literature DB >> 6773716

Valproic acid dosage and plasma protein binding and clearance.

A T Bowdle, I H Patel, R H Levy, A J Wilensky.   

Abstract

Valproic acid clearance was determined in six normal subjects during a single-dose (250-mg) study and multiple-dose experiments of 500, 1,000, and 1,500 mg/day. Eight consecutive oral doses were taken at 12-hr intervals at each dosing level. Valproate levels and protein binding were determined at steady state. Clearance declined 20% from 8.33 +/- 2.44 to 6.67 +/- 1.25 ml/hr/kd between the single-dose and the 500-mg/day steps (p = 0.05). Clearance was unchanged between the 500- and 1,000-mg/day steps despite a 44% increase in mean free fraction (0.0703 +/- 0.0381 vs 0.1011 +/- 0.0438, p < 0.05), implying a balanced opposing decline in intrinsic clearance (from 89.2 +/0 71.0 to 72.0 +/- 20.8 ml/hr/kg; p = 0.025). In four subjects completing the 1,500-mg/day step, clearance increased from 6.76 +/- 1.48 ml/hr/kg (1,000- mg/day) to 8.20 +/- 1.62 ml/hr/kg, corresponding to a further increase in free fraction. Free fraction varied within a single dosing interval (%SD = 11% to 49%). The apparent dose-related decline in intrinsic clearance suggests autoinhibition or saturation of metabolism.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6773716     DOI: 10.1038/clpt.1980.192

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  30 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

Review 2.  Therapeutic drug monitoring in pregnancy: rationale and current status.

Authors:  C Knott; F Reynolds
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 3.  Plasma protein binding of drugs in pregnancy and in neonates.

Authors:  L J Notarianni
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

Review 4.  Dose-related adverse effects of anticonvulsants.

Authors:  A S Troupin
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

5.  Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.

Authors:  Kim Vanstraelen; Joost Wauters; Ine Vercammen; Henriette de Loor; Johan Maertens; Katrien Lagrou; Pieter Annaert; Isabel Spriet
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

Review 6.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

7.  Rectal administration of sodium valproate in children.

Authors:  E Scanabissi; D Dal Pozzo; E Franzoni; C Galloni; G Mengoli; R Calivà
Journal:  Ital J Neurol Sci       Date:  1984-06

Review 8.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

9.  First-dose and steady-state pharmacokinetics of valproic acid in children with seizures.

Authors:  K Hall; N Otten; J Irvine-Meek; M Leroux; D Budnick; M Verma; S S Seshia
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

10.  Plasma protein-binding and CSF concentrations of valproic acid in man following acute oral dosing.

Authors:  W G Rapeport; A D Mendelow; G French; P MacPherson; E Teasdale; E Agnew; G G Thompson; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.